![](/assets/artwork/1x1-42817eea7ade52607a760cbee00d1495.gif)
500 集
![](/assets/artwork/1x1-42817eea7ade52607a760cbee00d1495.gif)
OncLive® On Air OncLive® On Air
-
- 健康與體能
In OncLive® On Air, you can expect to hear interviews with academic oncologists on the thought-provoking oncology presentations they give at the OncLive® State of the Science Summits. The topics in oncology vary, from systemic therapies, surgery, radiation therapy, to emerging therapeutic approaches in a particular type of cancer. This includes lung cancer, breast cancer, gastrointestinal cancers, hematologic malignancies, gynecologic cancers, genitourinary cancers, and more.
-
Miller Discusses the Use of Selinexor in TP53 Wild-Type Advanced Endometrial Cancer
Dr Miller discusses findings from the SIENDO trial of selinexor maintenance therapy in patients with TP53 wild-type advanced endometrial cancer.
-
Park and Sonpavde on Sacituzumab Govitecan Plus Enfortumab Vedotin in Metastatic Urothelial Cancer
Drs Park and Sonpavde discuss findings from the phase 1 DAD trial, as well as a schema for the frontline management of metastatic urothelial carcinoma.
-
Bui and Kelly Discuss the Utility of Nab-Sirolimus in Advanced Malignant PEComa
Drs Bui and Kelly discuss key long-term findings from the AMPECT trial investigating nab-sirolimus in patients with advanced malignant PEComa.
-
Curigliano on the DESTINY-Breast06 Trial in HER2-Low and -Ultralow Metastatic Breast Cancer
Dr Curigliano discusses the DESTINY-Breast06 trial of trastuzumab deruxtecan in patients with HER2-low or HER2-ultralow metastatic breast cancer.
-
Orlowski on Isa-VRd in Transplant-Ineligible Multiple Myeloma
Dr Orlowski discusses key efficacy data from the IMROZ trial of Isa-VRd in newly diagnosed, transplant-ineligible multiple myeloma.
-
Park and Sonpavde on Nivolumab Plus Gemcitabine/Cisplatin in Cisplatin-Eligible Urothelial Cancer
Drs Park and Sonpavde discuss the CheckMate901 trial, which showed survival improvements with nivolumab plus chemotherapy in metastatic urothelial cancer.